

1 **Antigen production and development of an indirect ELISA based on the nucleocapsid protein to detect**
2 **human SARS-CoV-2 seroconversion**

3
4 Marcelo S. Conzentino¹, Karl Forchhammer², Emanuel M Souza³, Fábio O. Pedrosa³, Meri B. Nogueira⁴,
5 Sônia M. Raboni⁴, Fabiane G. M. Rego⁵, Dalila L. Zanette⁶, Mateus N. Aoki⁶, Jeanine M. Nardin⁷, Bruna
6 Fornazari⁷, Hugo M. P. Morales⁷, Paola A. F. Celedon⁸, Carla V. P. Lima⁸, Sibelle B. Mattar⁸, Vanessa H.
7 Lin⁸, Luis G. Morello^{6,8}, Fabricio K. Marchini^{6,8}, Lucas Bochnia Bueno⁹, Rodrigo A. Reis¹ and Luciano F.
8 Huergo^{1*}

9
10 From the: ¹Setor Litoral, UFPR Matinhos, PR, Brazil; ²Interfakultäres Institut für Mikrobiologie und
11 Infektionsmedizin der Eberhard-Karls Universität Tübingen, Germany; ³Biochemistry and Molecular
12 Biology Department, UFPR Curitiba, PR, Brazil; ⁴Complexo Hospital das Clínicas, UFPR Curitiba, PR,
13 Brazil; ⁵Post-Graduation Program in Pharmaceutical Sciences, UFPR, Curitiba, PR, Brazil; ⁶ Instituto Carlos
14 Chagas – FioCruz, PR, Brazil; ⁷Hospital Erasto Gaertner, Curitiba, PR, Brazil; ⁸Instituto de Biologia
15 Molecular do Paraná, IBMP, Curitiba, PR, Brazil. ⁹Microbiology, Parasitology and Pathology Post Graduate
16 Program, UFPR, Curitiba, PR, Brazil.

17
18 * To whom correspondence should be addressed: Luciano F. Huergo, Tel: +55 41 996765856, E-mail:
19 luciano.huergo@gmail.com

20 Key words: SARS-CoV-2; COVID-19; immunological test; ELISA; Nucleocapsid protein

21

22

23

24

25

26

27 **Abstract**

28 Serological assays are important tools to identify previous exposure to SARS-CoV-2,
29 helping to track COVID-19 cases and determine the level of humoral response to SARS-CoV-2
30 infections and/or immunization to future vaccines. Here the SARS-CoV-2 nucleocapsid protein was
31 expressed in *Escherichia coli* and purified to homogeneity and high yield using a single
32 chromatography step. The purified SARS-CoV-2 nucleocapsid protein was used to develop an
33 indirect enzyme-linked immunosorbent assay for the identification of human SARS-CoV-2
34 seroconverts. The assay sensitivity and specificity were determined analyzing sera from 140 PCR-
35 confirmed COVID-19 cases and 210 pre-pandemic controls. The assay operated with 90%
36 sensitivity and 98% specificity; identical accuracies were obtained in head-to-head comparison with
37 a commercial ELISA kit. Antigen coated plates were stable for up to 3 months at 4°C). The ELISA
38 method described is ready to mass production and will be an additional toll to track COVID-19
39 cases.

40

41

42

43

44

45

46

47

48

50 **Introduction**

51 In December 2019, health authorities in Wuhan, China, reported cases of patients with
52 pneumonia of unknown epidemiological causes, linked to a seafood/animal market. The pathogen in
53 these cases has been identified, through viral isolation, electron microscopy and RNA sequencing,
54 as a new beta-coronavirus called SARS-CoV-2 (Zhu *et al.*, 2020). Shortly after its emergence in
55 China, SARS-CoV-2 spread rapidly across the world. According to the John Hopkins University
56 website (<https://coronavirus.jhu.edu/map.html>), on 01/02/2021, more than 100 million cases of
57 COVID-19 have been registered worldwide and the disease was responsible for 2,236,000 deaths.

58 Serological assays are important for epidemiological surveillance studies to monitor
59 COVID-19 cases (Petherick, 2020). The structural Nucleocapsid (N) protein is known to be a major
60 antigen of coronavirus producing a strong humoral response in humans (Cheng *et al.*, 2007).
61 Furthermore, the SARS-CoV-2 Nucleocapsid protein can be used as antigen to detect COVID-19
62 cases without significant cross-reactivity with common cold coronavirus (den Hartog *et al.*, 2020).
63 Here we describe the develop an indirect enzyme-linked immunosorbent assay (ELISA) which
64 allowed accurate detection human anti- IgG SARS-CoV-2 seroconversion.

65

66 **Results and Discussion**

67 A codon optimized synthetic gene was obtained and cloned into the pET28a vector to allow
68 the expression of an N-terminal 6xHis tagged SARS-CoV-2 N protein in *Escherichia coli* BL21
69 (λ DE3) (Huergo *et al.*, 2020; F. Huergo *et al.*, 2021). The viral protein was highly expressed and
70 remained partially soluble in *E. coli* cell extracts (Fig. 1A). The protein was purified using a 5 ml
71 His-trap affinity column (Cytiva) followed by elution with an imidazole gradient. The His-tagged
72 SARS-CoV-2 N protein eluted at 300 mM of imidazole to apparent homogeneity on Coomassie
73 stained SDS-PAGE (Fig. 1A). Typical protein yield was ~8 mg per 100 ml of culture, the antigen
74 was stored for up to 4 months at -20°C.

75 The purified N protein was diluted in buffer and used to coat 96 well polystyrene plates
76 overnight at 4⁰C. Plates were blocked with skimmed milk and serum from a COVID-19 positive
77 case and a negative control serum were serial diluted and placed into the wells of pre-coated plates.
78 The presence of IgG reacting with the SARS-CoV-2 N protein was revealed by incubating with
79 secondary anti-human IgG -HPR followed by chromogenic substrate TMB. The COVID-19
80 positive serum showed strong reaction with the N protein even at high dilutions (Fig. 1B). On the
81 other hand, the negative control serum showed only minor background cross reaction in low
82 dilutions (Fig. 2A). The OD450nm response vs serum dilution of the positive serum was linear
83 between the 1,600 to 25,600 dilutions with $R^2 = 0.995$ (Fig. 1C). This positive serum was used as a
84 positive control throughout this study, the inter assay CV% was 7.2% (same sample run in 12
85 different plates in duplicate). The mean intra assay CV% was 7.6% (mean CV% was obtained from
86 duplicate 96 samples x 12 plates).

87

88 **Material and Methods**

89

90 **Expression and purification of recombinant SARS-CoV-2 Nucleocapsid protein (N-protein)**

91 A codon optimized synthetic gene expressing the full-length SARS-CoV-2 N-protein
92 (Uniprot QHD43423.2) was obtained and cloned into pET28a by General Biosystems (F. Huergo *et*
93 *al.*, 2021). This plasmid was named pLHSarsCoV2-N and transformed into *E. coli* BL21 (λ DE3)
94 enabling the expression of N-terminal His-tagged N-protein after induction with IPTG. The cells
95 were growth in 100 ml LB medium at 120 rpm at 37°C to OD_{600nm} of 0.4. The incubator
96 temperature was lowered to 16°C, after 30 min, IPTG was added to a final concentration 0.3 mM
97 and the culture was kept at 120 rpm at 16°C over/night. Cells were collected by centrifugation at
98 3,000 xg for 5 min. The cell pellet was resuspended in 20 ml of buffer 1 (Tris-HCl pH 8 50 mM,
99 KCl 100 mM, glycerol 10%). Cells were disrupted by sonication on an ice bath. The soluble
100 fraction was recovered after centrifugation at 20,000 xg for 20 minutes and loaded onto a 5 ml His-

101 Trap column (Cytiva), which had been previously equilibrated with buffer 1. The column was
102 washed with 10 ml of buffer 1 and bound proteins were eluted with buffer 1 containing increasing
103 concentrations of imidazole. The His-tagged N-protein eluted at 300 mM imidazole. The final
104 protein preparation yield was ~ 8 mg and was homogeneous as judged by SDS-PAGE analysis. The
105 purified protein was stored in aliquots at 4°C for one week or at -20°C for up to four months.

106

107 **Human samples**

108 Samples were collected at the Hospital de Clínicas (CHC/UFPR), Hospital Erasto
109 Gaertner, Hospital do Trabalhador and Secretária Municipal de Saúde de Guaratuba. Samples for
110 serological analysis comprised both serum and plasma-EDTA. COVID-19 positive cases were
111 confirmed by the detection of SARS-CoV-2 RNA by real-time RT-PCR from nasopharyngeal
112 sample swabs. The time point of sampling of serum ranged from 1 to 70 days after onset of
113 symptoms. The cohort of 210 negative controls consisted of pre pandemic samples. The
114 Institutional Ethics Review Board of CHC/UFPR (n# 30578620.7.0000.0008), CEP/HEG (n#
115 31592620.4.1001.0098) and (CEP/HT n# 31650020.5.0000.5225) approved this study.

116

117 **ELISA assays**

118 The purified SARS-CoV-2 N-protein was diluted to 2 ng/μl in 50 mM Tris-HCl pH 8, 100
119 mM KCl, 10% (v/v) glycerol and 0.1 ml aliquots were transferred to the wells of ELISA plates
120 (Olen) and incubated overnight at 4°C. Unbound excess protein was removed, and wells were
121 washed twice with 0.2 ml of 1x TBST buffer pH 7.6 (Tris 2.42 g.l⁻¹, NaCl 8 g.l⁻¹ and tween 80 0.1%
122 v/v). Wells were blocked with 0.2 ml 3% (w/v) skimmed milk in 1x TBST overnight at 4°C. The
123 serum was diluted at 1:1,000 in 1x TBST containing 1% (w/v) skimmed milk and 0.1 ml were
124 loaded onto the ELISA duplicate wells following by incubation at room temperature for 1 hour. The
125 wells were washed three times with 0.2 ml of 1x TBST followed by incubation with 0.1 ml of anti-
126 human IgG-HPR from goat (Thermo Fisher - cat number 62-8420) diluted 1:3,000 in 1x TBST.

127 Wells were washed three times with 0.2 ml of 1x TBST. The HPR substrate TMB (Thermo Fisher -
128 cat number 00-2023) was added to the wells (0.1 ml). The reaction was stopped after 10 min
129 incubation at room temperature by addition of 0.1 ml 1M HCl. The plates were put on the top of a
130 white light transilluminator device and photographed. Samples were run in duplicates and data were
131 reported as % of a positive reference serum. The optical density was measured at 450 nm using a
132 TECAN M Nano plate reader (TECAN) monochromator at bandwidth 9 nm and 25 flashes.

133 The commercial Euroimmun Anti-SARS-CoV-2 ELISA IgG test was used following the
134 manufacturer's instructions.

135

136 **Data analysis**

137 One COVID-19 positive serum was used as a positive control and reference throughout the
138 study. All data were expressed as % of this positive control before applying Receiver Operating
139 Analysis using GraphPad Prism 7.0. Statistical analyses were performed using the *t* test.

140

141


142

143

144

145

Fig. 1



146

147

148 **Fig 1. Purification of the SARS-CoV-2 Nucleocapsid protein and serum dilution analysis on**
149 **ELISA.** A) SDS-PAGE analysis of purified His-tagged SARS-CoV-2 N protein. Lane 1, whole cell
150 extract; Lane 2, soluble fraction; Lane 3, insoluble fraction; Lane 4, column flow through; Other
151 lanes, imidazole gradient, the N protein is indicated by an arrow and eluted at 300 mM imidazole. B)
152 The serum from a COVID-19 positive case and from a negative control were serially diluted and
153 analyzed using indirect ELISA, the data were recorded photographically. C) The data derived from
154 the COVID-19 positive case was expressed as OD values vs reciprocal dilution; the dashed line
155 indicates the dilution used during this study.

156

157 To validate our ELISA assay to detect SARS-CoV-2 seroconversion in humans a cohort
158 consisting of 140 PCR-confirmed COVID-19 cases and 210 pre-pandemic negative controls were
159 used. The pre-pandemic control sera produced only background signal which were clearly
160 distinguished from the PCR-confirmed COVID-19 cases (Fig. 2A). The age of the negative cohort

161 ranged from 21 to 86 years of age (mean = 62). It is likely that most of these subjects had
162 experienced prior infections with common coronavirus (229E, NL63, OC43, and HKU which
163 usually cause mild upper-respiratory tract disease, like the common cold). These data suggest that
164 our ELISA assay shows negligible cross reactivity for IgG raised against common coronavirus.
165 However, it is worth mentioning that we detected 4 reactive pre-pandemic samples whose signals
166 were above the established cutoff thereby being classified as false positives (Fig. 2A). Such
167 reactivity could be potentially explained by cross reaction with IgG raised against common
168 coronavirus.

169 The ELISA method operated with an area under the ROC curve of 0.96 (Fig. 2B), the cut
170 off the assay was set at 90% sensitivity and 98% specificity. These values are in the same range for
171 other SARS-CoV-2 immunological IgG testes described previously (Cai *et al.*, 2020; den Hartog *et*
172 *al.*, 2020; Rikhtegaran Tehrani *et al.*, 2020). It is worth mentioning that among the PCR-confirmed
173 COVID-19 cases, 32 samples were in the early stage of infection (≤ 10 days after PCR detection)
174 and this may explain the low sensitivity. Indeed, if only samples collected ≤ 10 days after PCR
175 detection were considered, the sensitivity dropped to 81%. It is also worth mentioning that 40
176 samples of the COVID-19 positive cohort were from asymptomatic/mild COVID-19 cases which
177 are known to induce lower humoral response to SARS-CoV-2 infections (Long *et al.*, 2020).
178 Indeed, our analysis confirmed that the IgG titer was significantly lower in mild versus hospitalized
179 COVID-19 patients (Fig. 2C).

180

181

182


183

184

185

186

Fig. 2



188

189 **Fig 2. IgG seroconversion response to SARS-CoV-2 infection.** A) The OD was expressed as % of
 190 reference serum for negative control samples (n=210) and PCR-confirmed COVID-19 cases
 191 (n=140). B) Receiver Operating Characteristics analysis (ROC) of the data described in A. C)
 192 Comparison between the IgG signal reacting with the SARS-CoV-2 Nucleocapsid protein in Mild
 193 and Hospitalized PCR-confirmed COVID-19 cases. Groups were compared using the T test.

194

195

A panel of 90 samples was analyzed in parallel by our developed ELISA and the
 196 Euroimmun Nucleocapsid-based IgG ELISA. All the 44 pre-pandemic negative samples analyzed
 197 were negative in both tests confirming the high specificity of the assays. Out of the 46 PCR
 198 confirmed COVID-19 samples, both tests missed 4 samples (false negatives). One sample was
 199 negative in both tests and three samples were uniquely negative in each of the two different tests.
 200 These data support that our ELISA performed with similar sensitivity to the commercial
 201 Euroimmun ELISA test.

202

203

204

205

206

207

208

In conclusion, here we describe a high yield and simple method to purify the SARS-CoV-
 2 Nucleocapsid antigen using only one simple affinity chromatography step. The antigen
 preparation was used to develop an indirect ELISA which allowed accurate detection of SARS-
 CoV-2 seroconversion in humans. The developed assay is ready for mass production in order to
 help to track COVID-19 cases specially in developing countries where access to molecular test is
 limited.

209

210

211 **Acknowledgments**

212 This work was supported by the Alexander von Humboldt foundation and The Federal
213 University of Paraná, Brazil. MC received an undergraduate technological development fellowship
214 from CNPq (PIBIT - UFPR).

215 **Conflict of interest**

216 The authors declare that they have no conflict of interest.

217 **References**

218 Cai, X., Chen, J., li Hu, J.-, Long, Q., Deng, H., Liu, P., *et al.* (2020) A Peptide-Based Magnetic
219 Chemiluminescence Enzyme Immunoassay for Serological Diagnosis of Coronavirus Disease 2019.
220 *J Infect Dis* .

221 Cheng, V.C.C., Lau, S.K.P., Woo, P.C.Y., and Kwok, Y.Y. (2007) Severe acute respiratory
222 syndrome coronavirus as an agent of emerging and reemerging infection. *Clin Microbiol Rev* .

223 F. Huergo, L., A. Selim, K., S. Conzentino, M., C. M. Gerhardt, E., R. S. Santos, A., Wagner, B., *et*
224 *al.* (2021) Magnetic Bead-Based Immunoassay Allows Rapid, Inexpensive, and Quantitative
225 Detection of Human SARS-CoV-2 Antibodies. *ACS Sensors* **0**.

226 Hartog, G. den, Schepp, R.M., Kuijper, M., GeurtsvanKessel, C., Beek, J. van, Rots, N., *et al.* (2020)
227 SARS-CoV-2–Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach
228 Accounting for Accurate Seroprevalence. *J Infect Dis* .

229 Huergo, L.F., Conzentino, M.S., Gerhardt, E.C.M., Santos, A.R.S., Pedrosa, F. de O., Souza, E.M.,
230 *et al.* (2020) Magnetic bead-based ELISA allow inexpensive, rapid and quantitative detection of
231 human antibodies against SARS-CoV-2. *medRxiv* .

232 Long, Q.X., Tang, X.J., Shi, Q.L., Li, Q., Deng, H.J., Yuan, J., *et al.* (2020) Clinical and
233 immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat Med* .

234 Petherick, A. (2020) Developing antibody tests for SARS-CoV-2. *Lancet* .

235 Rikhtegaran Tehrani, Z., Saadat, S., Saleh, E., Ouyang, X., Constantine, N., DeVico, A.L., *et al.*
236 (2020) Specificity and Performance of Nucleocapsid and Spike-based SARS-CoV-2 Serologic
237 Assays. *medRxiv* .

238 Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., *et al.* (2020) A novel coronavirus from
239 patients with pneumonia in China, 2019. *N Engl J Med* .

240

241

